The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Open accessAbstract
Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44 years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective medications existed for the treatment of schizophrenia. This review summarizes key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia, including clozapine in treatment-resistant patients. In the most comprehensive meta-analysis of randomized controlled trials conducted in multi-episode schizophrenia, antipsychotics outperformed placebo regarding total symptoms, positive symptoms, negative symptoms, depressive symptoms, quality of life and social functioning. Amongst these outcomes, the standardized mean difference for overall symptoms was largest, that is, 0.47 (95% credible interval = 0.42–0.51), approaching a medium effect size, being reduced to 0.38 when publication bias and small-trial effects were accounted for. A comparison of two meta-analyses indicated that first-episode patients, compared with multi-episode patients, were more likely to have at least minimal treatment response [⩾20% Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) score reduction: 81% versus 51%] and good response (⩾50% PANSS/BPRS score reduction: 52% versus 23%). In multi-episode schizophrenia, no response or worsening after 2 weeks of a therapeutic antipsychotic dose was highly predictive of not achieving a good response at endpoint (median treatment = 6 weeks: specificity = 86%; positive predictive value = 90%), suggesting a change in treatment should be considered in such cases. In first-episode psychosis, adequately dosed antipsychotic treatment trials for more than 2 weeks are recommended before using no response or worsening as a decision point for aborting a given antipsychotic. In clearly defined treatment-resistant schizophrenia, clozapine generally outperformed other antipsychotics, especially when dosed appropriately (target = 3–6 months’ duration; trough clozapine level ⩾350–400 μg/L) with a response rate (⩾20% PANSS/BPRS) of 33% by 3 months of treatment. High antipsychotic doses and psychotropic combinations are unlikely to be superior to standard doses of antipsychotic monotherapy. Acute antipsychotic efficacy in schizophrenia depends on the targeted symptom domain (greater efficacy: total and positive symptoms, lesser efficacy: negative symptoms, depressive symptoms, social functioning and quality of life). Greater antipsychotic efficacy is associated with higher total baseline symptom severity, treatment-naïveté/first-episode status, shorter illness duration, and trials that are nonindustry sponsored and that have a lower placebo effect. The heterogeneity of antipsychotic response across individuals and key symptom domains, the considerable degree of nonresponse/treatment resistance in multi-episode patients, and the adverse effect potential of antipsychotics are major limitations, underscoring the need to develop new medications for the treatment of schizophrenia. Drug development should include matching patient subgroups, which are identified by means of clinical and biomarker variables, to mechanisms of action of novel medications, targeting specific symptom domains, and investigating mechanisms of action other than dopaminergic blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antipsychotic medication is the first line of treatment for SSD, showing effectiveness in managing positive symptoms like hallucinations and delusions but showing limited efficacy in addressing negative symptoms and cognitive impairment.10–12”
From Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders—Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial. (2026) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,328
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,187
Self-citationKahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Self-citation
Research works printed but not linked: 12
- World Health Organisation, 2001, The WHO World Health Report 2001 - Mental Health: New Understanding, New Hope
- A full list of the papers available in the Special Collection on Antipsychotics: Advances, Limitations, and Alternatives in Therapeutic Advances in Psychopharmacology is available at: http://journals.sagepub.com/page/tpp/special-collection/antipsychotics
- 10.1176/ajp.2006.163.4.743 · DOI
- Royal College of Psychiatrists, 2014, CR190 Consensus statement on High-dose Antipsychotic medication
- Ackenheil M, 1977, Psychotherapeutic drugs: part II, 923
- Idanpaan-Heikkila J, Lancet, 1975
- National Institute for Health and Care Excellence (NICE), 2014, Clinical guideline [CG178]
- 10.1176/ajp.151.12.1744 · DOI
- Albert C., 2017, Int J Mol Sci, 18
- Zhao S, 2015, Cochrane Database Syst Rev
- Dieterich M, 2017, Cochrane Database Syst Rev
- Carmona VR, 2017, Int J Occup Med Environ Health, 30, 345
Cited by
Sorted by citations
Items 201–259 of 259
Meyer, J. M., & Stahl, S. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781009002103.008
Omeiza, N. A., Bakre, A. G., Abdulrahim, H. A., Isibor, H., Ezurike, P. U., Sowunmi, A. A., Ben‐Azu, B., & Aderibigbe, A. O. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089472
Tardive Dyskinesia Following Low-Dose Risperidone
Rokon, A. E., Alsomali, F. A., Alrasheed, M. A., Alharbi, A. D., Alhamadh, M. S., Alqahtani, A. M., Alhamidy, F. K., & Alotaibi, M. R. (2022) · Cureus · doi:10.7759/cureus.32319
Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia
Nasyrova, R. F. (2022) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2022-4-101-106
Shamnad, M., Antony, C., Ajmajashy, Z., Muktha, K., & Huwais, M. (2023) · Indian Journal of Pharmacy Practice · doi:10.5530/097483261180
The dual hit hypothesis of schizophrenia
Guerrin, C. G. J. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.791866719
Effectiveness of spironolactone on schizophrenia symptoms: A double-blind randomized clinical trial
Hoghoughi, N., Alizadeh, N. S., Maroufi, A., Rezaei, F., & Esfandiari, G.-R. (2023) · Shenakht Journal of Psychology and Psychiatry · doi:10.32598/shenakht.10.4.119
Toksik Maddelerin Sınıflandırılması
Genç, M. K., Bülbül, T. T., Şimşek, S. Z., Arslan, Z., Zengin, S., & Türkmen, Z. (2023) · doi:10.5152/6404
Adli Toksikolojinin Tanımı ve Tarihsel Gelişimi
Açıkkol, M. (2023) · doi:10.5152/6401
Adli Toksikolojide Yasal Uygulamalar ve Raporlama
Açıkkol, M. (2023) · doi:10.5152/6408
Adli Toksikoloji Laboratuvarı ve Yöntem Geçerliliği
Bülbül, T. T., Yayla, M., & Mercan, S. (2023) · doi:10.5152/6407
Zehirlenmelere Adli ve Klinik Yaklaşım
Bavunoğlu, I. (2023) · doi:10.5152/6403
Mercan, S., & Zengin, S. (2023) · doi:10.5152/6402
Adli Toksikolojide Kullanılan Deliller ve Numune Hazırlama Yöntemleri
Zengin, S., Kuloglu, M., TÜRKMEN, Z., & Mercan, S. (2023) · doi:10.5152/6405
Adli Toksikolojide Yenilikçi Yaklaşımlar
Şimşek, S. Z., Kuloglu, M., & Mercan, S. (2023) · doi:10.5152/6409
Pierce, Z. P., Bogatz, A. S., Johnson, E. R., Lear, B. E., Nelson, C., & Black, J. M. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.029
RetractedPsychopharmacological Treatment of Schizophrenia
Singh, N., Ganesh, S., & D’Souza, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00177-9
Brabander, E. Y. D., van Amelsvoort, T., van Westrhenen, R., & GROUP Investigators (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241279022
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00011-9
Zahariichuk, O. (2024) · Wiadomości Lekarskie · doi:10.36740/wlek/195547
Prescribing in the acute mental health inpatient context
Ayela-Uwangue, S., & Hemingway, S. (2025) · Journal of Prescribing Practice · doi:10.12968/jprp.2025.0022
Martín-Cuevas, C., Ramos‐Herrero, V. D., Flores‐Martínez, Á., González‐Recio, I., Martínez‐Chantar, M. L., Leza, J. C., Meana, J. J., Crespo‐Facorro, B., & Sánchez-Hidalgo, A. C. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04282-1 · Cited by 1
O’Neill, J. R., Wilson, C., Horowitz, M. A., McLean, S. L., Faisal, M., Dixon, M., Couchman, L., Lawlor, K., & Crowther, G. J. E. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10831 · Cited by 1
Factors Affecting Ketamine Metabolism Within the Cytochrome P450 System
Petrică, A., Bzovii, F., Botea, M. O., Marza, A. M., & Barsac, C. R. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_21
Sex differences in latent inhibition and their implications for psychotic disordersPreprint
Mawson, E. R., Hall, J., & Thomas, K. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.677991
Dash, N., Sharma, I. L., Gehlot, A., Rathore, R., & Seervi, A. (2025) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20251205
Hartmann, S.-M., Garcia, P., Heider, J., Vogel, S., Wüstner, L.-S., Wüst, R., Fallgatter, A. J., & Volkmer, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03384-4
Zhao, H., Zhu, G., Zhu, T., Ding, B., Xu, A., Gao, S., Chao, Y., Li, N., Chen, Y., Wang, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26753221
Guo, L.-K., Su, Y., Zhang, Y., Yu, H., Lu, Z., Li, W.-Q., Yang, Y.-F., Xiao, X., Yan, H., Lu, T.-L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23290495
Nasrallah, H. A., Weiden, P. J., Walling, D. P., Du, Y., Yao, B., Yagoda, S., & Claxton, A. (2021) · Figshare · doi:10.6084/m9.figshare.16778366
Guo, L.-K., Su, Y., Zhang, Y., Yu, H., Lu, Z., Li, W.-Q., Yang, Y.-F., Xiao, X., Yan, H., Lu, T.-L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23290498
Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8284834/v1
Feng, Z., Zhu, L., Li, W., Wang, F., Cheng, Q., Yang, H., Huang, Y., Gao, W., Lu, H., Wang, J., et al. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.111904
Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account
Vin, R., Galbraith, J., Seabury, R. D., Yi, H. Y., Hernández-Busot, G., Oland, L., Epié, B., Trainer, A. E., Fredericks, C. A., & Powers, A. R. (2026) · Brain Communications · doi:10.1093/braincomms/fcag001 · Cited by 1
Sharma, T., Kumari, P., & Bali, A. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2617606
Pieri, M. D., Rochas, V., Petignat, C., Molo, G., Bertrand, N., Apostolopoulou, D., Godel, M., Kirschner, M., & Kaiser, S. (2026) · medRxiv · doi:10.64898/2026.01.26.26344882
The role of ADAMTS2 in schizophrenia: Validation in a novel transgenic mouse modelPreprint
Crespo‐Facorro, B., Martín-Cuevas, C., Flores‐Martínez, Á., Ramos‐Herrero, V. D., Moreno-Mellado, A., & Sánchez-Hidalgo, A. C. (2026) · Research Square · doi:10.21203/rs.3.rs-8345763/v1
Zierhut, M. M., Hartter, N., von Eisenhart-Rothe, V., Hahne, I., Bergmann, N., Kraft, J., Braun, A., Bayer, M., Ta, T. M. T., Ripke, S., et al. (2026) · Ecopsychology · doi:10.1177/19429347261419214
Lynch, S. T., Renard, K. B., Chaia, A. I., Cohen, L. J., & Kymissis, C. M. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.03.015
Kwon, H.-Y., Bae, J., Lee, Y., Rodgers, R. F., Bui, É., & Kim, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9406344/v1
Shao, M., Zhu, T., Hu, X., Fang, X., Pan, X., Wen, L., Dai, P., Amdanee, N., Zhang, L., Xu, Y., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261432764
Peripheral complement C3 and C4 are associated with clinical features of schizophrenia
Szwajca, M., Śmierciak, N., Biesaga, B., Donicz, P., Szwajca, K., & Pilecki, M. W. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1767438 · Cited by 1
Lynch, S. T., Chaia, A. I., Renard, K. B., Cohen, L. J., & Kymissis, C. M. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.04.018
Hahne, I., Zierhut, M. M., Bergmann, N., Fässler, L., Töbelmann, L., Opper, F., Hahn, E., Ta, T. M. T., Calvano, C., Bajbouj, M., et al. (2026) · Psychiatry Research Communications · doi:10.1016/j.psycom.2026.100262
Zhang, H., Li, W., Zhi, S., Fang, S., Li, J., Zhang, T., Li, M., Lang, J., Wang, L., Feng, Y., et al. (2026) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2026.105612
Khan, M. U., & Hasan, S. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349877
Ladret, H., Lupori, L., Sieni, L., Stroukov, E., Kanamori, T., Ulrich, S., Schneider, E., Deuring, G., Brühl, A. B., & Keller, G. B. (2026) · eLife · doi:10.7554/elife.111896
Ladret, H., Lupori, L., Sieni, L., Stroukov, E., Kanamori, T., Ulrich, S., Schneider, E., Deuring, G., Brühl, A. B., & Keller, G. B. (2026) · eLife · doi:10.7554/elife.111896.1
Tackling pharmaceutical pollution under the One Health framework
Zhu, G., Su, J., Lv, M., Zhou, X., Zhang, W., Li, M., Wang, T., Guo, J., Liao, H., Qian, H., et al. (2026) · The Innovation · doi:10.1016/j.xinn.2026.101507 · Cited by 1
Hidayah, N., Ikawati, M., Amin, M. M., & Ikawati, Z. (2026) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000600
Thela, L. T., Nkambule, B. B., Msibi, Z. N. P., Ntlantsana, V., Paruk, S., Tomita, A. M., Xulu, K. R., & Chiliza, B. (2026) · Brain Sciences · doi:10.3390/brainsci16080867
Veloso, P., Gomes, M., Pires, M., Morgado, P. F., & Pereira, F. (2026) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.681
Dopamine antagonists and dynamic symptom networks in schizophrenia
Kenny, E. A., Brand, B. A., Ebrahimi, O. V., & McCutcheon, R. A. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10775
Ladret, H., Lupori, L., Sieni, L., Stroukov, E., Kanamori, T., Ulrich, S., Schneider, E., Deuring, G., Brühl, A. B., & Keller, G. B. (2026) · eLife · doi:10.7554/elife.111896.2
N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential
Rubio-Contreras, E., Pérez‐Toribio, A., Alvaro, P., Cosialls, A. M., & Morén, C. (2026) · Antioxidants · doi:10.3390/antiox15101277
Epigenetics processes involved in schizophrenia and antipsychotic treatment
MALIK, K., Davies, S. J. C., RAVINDRAN, N., & LUCA, V. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00024-4
Metadata
- Authors
- Haddad, P. M., & Correll, C. U.
- Affiliations
- University of Manchester (GB)
- Hofstra University (US)
- Corresponding author
- Haddad, Peter M.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-10-08
- Volume
- 8
- Issue
- 11
- Pages
- 303-318
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC6180374
- OpenAlex
- W2897156727
- Cited by
- 259
- References
- 74
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 45 · 2023: 46 · 2022: 31 · 2021: 33 · 2020: 23 · 2019: 12
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- schizophrenia, antipsychotic drugs, clozapine, treatment-resistant schizophrenia, first-episode psychosis, treatment response prediction, antipsychotic dosing, antipsychotic monotherapy, positive symptoms, negative symptoms, depressive symptoms, quality of life, social functioning, publication bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
